Carly Mcateer, MD - Medicare Family Practice in Scarborough, ME

Carly Mcateer, MD is a medicare enrolled "Family Medicine" physician in Scarborough, Maine. She went to University Of Nevada School Of Medicine and graduated in 2007 and has 17 years of diverse experience with area of expertise as Family Practice. She is a member of the group practice Maine Medical Partners, Mainehealth and her current practice location is 301c Us Route 1, Scarborough, Maine. You can reach out to her office (for appointments etc.) via phone at (207) 396-8600.

Carly Mcateer is licensed to practice in Maine (license number MD18534) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1699974311.

Contact Information

Carly Mcateer, MD
301c Us Route 1,
Scarborough, ME 04074-9701
(207) 396-8600
(207) 396-8632



Physician's Profile

Full NameCarly Mcateer
GenderFemale
SpecialityFamily Practice
Experience17 Years
Location301c Us Route 1, Scarborough, Maine
Accepts Medicare AssignmentsYes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Carly Mcateer attended and graduated from University Of Nevada School Of Medicine in 2007
  NPI Data:
  • NPI Number: 1699974311
  • Provider Enumeration Date: 07/12/2007
  • Last Update Date: 10/24/2013
  Medicare PECOS Information:
  • PECOS PAC ID: 3971796228
  • Enrollment ID: I20101020000037

Medical Identifiers

Medical identifiers for Carly Mcateer such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1699974311NPI-NPPES
1699974311MedicaidME

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207Q00000XFamily Medicine MD18534 (Maine)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Maine Medical CenterPortland, MEHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Maine Medical Partners9335043967789
Mainehealth75178605882067

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Carly Mcateer allows following entities to bill medicare on her behalf.
Entity NameMaine Medical Partners
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1467477349
PECOS PAC ID: 9335043967
Enrollment ID: O20031125000026

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Entity NameMainehealth
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1639194509
PECOS PAC ID: 7517860588
Enrollment ID: O20040206000472

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Entity NameMaine Medical Partners
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1598780447
PECOS PAC ID: 9335043967
Enrollment ID: O20040220000847

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Entity NameMaine Medical Partners
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1134144090
PECOS PAC ID: 9335043967
Enrollment ID: O20040331000191

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Entity NameMainehealth
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1790265502
PECOS PAC ID: 7517860588
Enrollment ID: O20040701000166

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more Medical News

› Verified 6 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Carly Mcateer is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Carly Mcateer, MD
272 Congress St,
Portland, ME 04101-3637

Ph: (207) 874-2466
Carly Mcateer, MD
301c Us Route 1,
Scarborough, ME 04074-9701

Ph: (207) 396-8600

News Archive

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

Study uncovers role for STING in regulating tumor response to DNA-damaging treatments

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING.

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

Read more News

› Verified 6 days ago


Family Medicine Doctors in Scarborough, ME

Mr. Gavin M Ducker, MD
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 300 Professional Dr Ste 2c, Scarborough, ME 04074
Phone: 207-883-7926    
Mrs. Kristyn Michelle Kee, FNP-C
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 96 Campus Dr, Scarborough, ME 04074
Phone: 603-303-0108    
Kristen Alyse Scopaz, MD
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 20 Mussey Rd, Scarborough, ME 04074
Phone: 207-885-1333    Fax: 207-885-1332
Gwendolyn Oguin, DO
Family Medicine
Medicare: Medicare Enrolled
Practice Location: 20 Mussey Rd, Suite 2, Scarborough, ME 04074
Phone: 207-885-1333    Fax: 207-885-1337
Dr. David Merrill, MD
Family Medicine
Medicare: Not Enrolled in Medicare
Practice Location: 69 Us Route 1, 6 Nonesuch Rd, Scarborough, ME 04074
Phone: 207-883-8100    
Felicia Jo Munster, FNP-BC
Family Medicine
Medicare: Medicare Enrolled
Practice Location: 100 Campus Dr, Scarborough, ME 04074
Phone: 207-396-7683    Fax: 207-396-7684
Dr. Howard Manning Chase, DO
Family Medicine
Medicare: Not Enrolled in Medicare
Practice Location: 438 Us Route 1, Scarborough, ME 04074
Phone: 207-883-4124    Fax: 207-883-0732

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.